Wells Fargo has increased its price target for Liquidia Technologies, attributing this adjustment to the anticipated growth of Yutrepia, the company's inhaled medication for pulmonary arterial hypertension. This revision reflects the bank's confidence in the product's market potential and its expected performance in the coming periods. The updated price target underscores the positive outlook for Liquidia Technologies as it continues to advance its therapeutic offerings.
Related Articles
Don't miss out on breaking stories and in-depth articles.